Cargando…
2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report
Cancers of unknown primary (CUP) account for 2%–5% of all diagnosed cancers and are always characterized with fast-paced aggression, early metastasis, and unpredictable spread patterns Mediastinum metastasis with unknown primary origin is extremely rare and with a poor prognosis and short survival....
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598860/ https://www.ncbi.nlm.nih.gov/pubmed/37886174 http://dx.doi.org/10.3389/fonc.2023.1242460 |
_version_ | 1785125647856697344 |
---|---|
author | Zhao, Wei Zhao, Nan Zhang, Manze Li, Zhihua Wang, Ning Shen, Wennan Dong, Yuemei Nie, Yanli Li, Zhaoxia |
author_facet | Zhao, Wei Zhao, Nan Zhang, Manze Li, Zhihua Wang, Ning Shen, Wennan Dong, Yuemei Nie, Yanli Li, Zhaoxia |
author_sort | Zhao, Wei |
collection | PubMed |
description | Cancers of unknown primary (CUP) account for 2%–5% of all diagnosed cancers and are always characterized with fast-paced aggression, early metastasis, and unpredictable spread patterns Mediastinum metastasis with unknown primary origin is extremely rare and with a poor prognosis and short survival. There is no literature to refer to for its treatment. Here, we reported a case of squamous cell CUP in the mediastinum. A 50-year-old male patient was admitted after multi-line treatment of low differentiated squamous cell carcinoma in the mediastinum diagnosed 8 months before. In August 2019, the patient went to a local hospital for cough and dyspnea for 2 weeks. Then, he was diagnosed with squamous cell carcinoma of unknown primary origin with multiple lymph nodes metastasis. The patient was featured with programmed cell death-ligand 1 (PD-L1) expression strongly positive in 90% of tumor cells and the combined positive score of 90 and a tumor mutation burden of 1.79 MUts/Mb and microsatellite stable phenotype. The patient was treated with anti-programmed cell death-1 (PD-1) antibodies in combination with chemotherapy and responded to the treatment. The patient showed stable disease to multi-line immunotherapy for more than 7 months and finally got a clinical benefit of 2-year survival benefit. In conclusion, immunotherapy targeting PD-1/PD-L1 in combination with chemotherapy may play a crucial role in the later-line treatment and palliative care of CUP. |
format | Online Article Text |
id | pubmed-10598860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105988602023-10-26 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report Zhao, Wei Zhao, Nan Zhang, Manze Li, Zhihua Wang, Ning Shen, Wennan Dong, Yuemei Nie, Yanli Li, Zhaoxia Front Oncol Oncology Cancers of unknown primary (CUP) account for 2%–5% of all diagnosed cancers and are always characterized with fast-paced aggression, early metastasis, and unpredictable spread patterns Mediastinum metastasis with unknown primary origin is extremely rare and with a poor prognosis and short survival. There is no literature to refer to for its treatment. Here, we reported a case of squamous cell CUP in the mediastinum. A 50-year-old male patient was admitted after multi-line treatment of low differentiated squamous cell carcinoma in the mediastinum diagnosed 8 months before. In August 2019, the patient went to a local hospital for cough and dyspnea for 2 weeks. Then, he was diagnosed with squamous cell carcinoma of unknown primary origin with multiple lymph nodes metastasis. The patient was featured with programmed cell death-ligand 1 (PD-L1) expression strongly positive in 90% of tumor cells and the combined positive score of 90 and a tumor mutation burden of 1.79 MUts/Mb and microsatellite stable phenotype. The patient was treated with anti-programmed cell death-1 (PD-1) antibodies in combination with chemotherapy and responded to the treatment. The patient showed stable disease to multi-line immunotherapy for more than 7 months and finally got a clinical benefit of 2-year survival benefit. In conclusion, immunotherapy targeting PD-1/PD-L1 in combination with chemotherapy may play a crucial role in the later-line treatment and palliative care of CUP. Frontiers Media S.A. 2023-10-11 /pmc/articles/PMC10598860/ /pubmed/37886174 http://dx.doi.org/10.3389/fonc.2023.1242460 Text en Copyright © 2023 Zhao, Zhao, Zhang, Li, Wang, Shen, Dong, Nie and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhao, Wei Zhao, Nan Zhang, Manze Li, Zhihua Wang, Ning Shen, Wennan Dong, Yuemei Nie, Yanli Li, Zhaoxia 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report |
title | 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report |
title_full | 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report |
title_fullStr | 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report |
title_full_unstemmed | 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report |
title_short | 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report |
title_sort | 2-year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598860/ https://www.ncbi.nlm.nih.gov/pubmed/37886174 http://dx.doi.org/10.3389/fonc.2023.1242460 |
work_keys_str_mv | AT zhaowei 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport AT zhaonan 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport AT zhangmanze 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport AT lizhihua 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport AT wangning 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport AT shenwennan 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport AT dongyuemei 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport AT nieyanli 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport AT lizhaoxia 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport |